Document 0640
 DOCN  M9590640
 TI    Basic science and clinical trials: interview with William Paul, director
       of the Office of AIDS Research. [interview by John S James]
       Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231
       ext. 5023.
 DT    9509
 AU    Paul W
 SO    AIDS Treat News. 1995 Feb 17;(no 217):1, 4-7. Unique Identifier :
       AIDSLINE AIDS/95700327
 AB    William E. Paul, Director of the Office of AIDS Research (OAR) at the
       U.S. National Institutes of Health (NIH), responded to questions
       addressing public concern that his proposal for more basic AIDS research
       will reduce clinical trial research intended to find treatments. Dr.
       Paul clarified the role of small, rapid, data-intensive, exploratory
       human trials. He stressed the need for a balanced approach to studying
       HIV to better understand the mechanisms of this disease without
       abandoning therapeutic research. He believes that smaller,
       laboratory-intensive, pathogenesis trials should be part of the overall
       effort and that conventional grant support should fund data-intensive
       trials. Dr. Paul also advocates clinical investigation on humans, due to
       the lack of animal models, using known parameters to see how the immune
       system responds. As a result of limited funding, Dr. Paul believes that
       research usefulness should be a criteria for funding. The suggestion
       that management consultants be brought in to assess the effectiveness of
       the system used in conducting the research is questioned. Dr. Paul
       states that while systems management professionals are good at the
       development end, they are not experienced at grappling with problems in
       discovery. Finally, Dr. Paul indicates that OAR's role is recognizing
       where the opportunities lie and finding ways of putting the resources
       there.
 DE    *Acquired Immunodeficiency Syndrome  Animal  *Clinical Trials  Disease
       Models, Animal  Human  Hydroxyurea/THERAPEUTIC USE  National Institutes
       of Health (U.S.)  *Research  Research Support  United States  NEWSLETTER
       ARTICLE  INTERVIEW

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).